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Drug-induced toxic epidermal necrolysis (TEN) and acute cutaneous graft-versus-host reaction (GVHR) under immunopreventive
therapy share some histopathological resemblance. So far, there are no serum biomarkers and no immunohistochemical criteria
distinguishing with confidence and specificity the skin lesions of TEN and GVHR. Both diseases present as an inflammatory cell-
poor necrotic reaction of the epidermis.This report compares three sets of 15 immunostaining patterns found in TEN, GVHR, and
partial thickness thermal burns (PTTB), respectively. Three series of 17 skin biopsies were scrutinized. Irrespective of the distinct
causal pathobiology of TEN and GVHR, similar secondary effector cells were recruited in lesional skin. Burns were less enriched
in cells of the monocyte-macrophage disease. These cells likely exert deleterious effects in TEN and GVHR and cannot be simply
regarded as passive bystanders. These life-threatening conditions are probably nursed, at least in part, by macrophages.
1. Introduction
Toxic epidermal necrolysis (TEN), formerly called under
its eponym Lyell’s syndrome, is a severe cutaneous adverse
reaction (SCAR) to drugs [1]. Conceptually, both TEN and
the Stevens-Johnson syndrome (SJS) are likely part of the
same continuum of clinical presentations [2–6], and they
are regarded to be likely distinct from erythema multi-
forme [7–9]. The precise TEN pathomechanism remains
unclear [1, 5, 10–12]. Some toxic metabolites and/or cytotoxic
inflammatory cells induce epithelial apoptosis and necro-
sis [5, 13–15]. Cytotoxic lymphocytes, regulatory T cells
(Treg),macrophages, and dermal dendrocytes (DD) are likely
involved, and they probably represent more than passive
bystanders [16–20].
Graft-versus-host reaction (GVHR), both in its acute
and chronic stages, is responsible for both potentially severe
morbidity and mortality [21, 22]. GVHR remains quite
frequent in susceptible groups of patients as about half of
recipients of allogeneic hematopoietic cell transplantation
(HCT) develop GVHR [23–25].This condition results from a
complex and intricate pathobiology sustained by interactions
between the donor and host innate and adaptive immune
responses. A number of lymphocyte subsets (naive, memory,
Treg, Th1, Th17, NK, . . . ) are involved, as well as eosinophils,
mesenchymal stem cells and the monocyte-macrophage lin-
eage including Factor XIIIa+ DD [26–30].
There is an overlap in a series of histopathological signs
between early GVHR and various other posttransplantation
diseases including some viral exanthems, immune recon-
stitution rash, and drug reactions [22]. The key points are
keratinocyte apoptosis and satellite cell necrosis [31–35]. In
absence of specific GVHR histopathological features, the
value of skin microscopy remained fairly limited for landing
support to the GVHR diagnosis or for ruling out other unre-
lated diseases. However, targeted immunohistochemistrywas
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Table 1: Patient demography.
Parameter GVHR TEN PTTB
M/F 10/7 6/11 9/8
Age, years (mean ± SD) 35 ± 8 39 ± 6 37 ± 10
occasionally reported to bring some decisive clues [26, 36–
42]. Both cell differentiation and tensegrity (shape) are
better highlighted using some relevant immunopathological
markers. It remains that some patients with GVHR develop
a drug-induced TEN or a GVHR-related TEN-like lesion
[43–46]. In some instances, the histopathological distinction
between both conditions remains notoriously difficult or
impossible to establish [27].
The aim of the present retrospective study was to revisit
the input of immunopathology in the diagnosis of and
distinction between cutaneous GVHR and TEN. The study
was focused on the histopathology of incipient erythematous
GVHR and TEN lesions with epidermal necrosis. Recent
partial thickness thermal burns (PTTB) were used as control
for epidermal destruction following physical injury.
2. Subjects and Methods
The study was approved by the Lie`ge University Hospital and
the local Ethics Committee of the Percy Military Teaching
Hospital in Clamart. Three series of 17 lesional skin biopsies
collected from untreated patients were retrieved from our
files. They had been diagnosed as GVHR, TEN, and PTTB,
respectively (Table 1). In each case, the epidermis was still
present and in close contact with the dermis. Sections (5𝜇m
thick) were cut from formalin-fixed paraffin-embedded biop-
sies and stained by hematoxylin and eosin. Since clues
from histopathology frequently fail to discriminate with
confidence cutaneous GVHR from SCAR, immunohisto-
chemistry targeting inflammatory cells, keratinocytes, and
dermal cells was used aiming at better discriminating the
three conditions. Paraffin sections were used for the avidin-
biotin peroxidase method. After a 1-hour incubation time
with each of the 15 primary antibodies (Table 2), slides
were washed in Tris-buffered saline (TBS) and incubated
for 30min with the secondary antibody (biotinylated swine
anti-rabbit, 1 : 300, Dakopatts). Slides were rinsed in TBS and
covered by the EnVision (Dakopatts, Glostrup, Denmark)
polymer-based revelation system. After TBS washing, Fast
Red (Dakopatts) was used as chromogen substrate. The last
steps consisted of counterstaining with Mayer’s hemalum.
Negative immunohistochemical controls were performed by
omitting or substituting the primary and the secondary
antibodies of the laboratory procedure.
Quantitative assessments were performed using com-
puterized image analysis (MOP videoplan Kontron, Eching,
Germany). Assessments were performed in a band 0.6mm
thick of the most superficial part of the skin. Cell counts
were expressed as medians per mm2 of tissue (epidermis
or dermis) section. Statistical comparisons were performed
between TEN and GVHR using the unpaired nonparametric
Mann-Whitney U test. Similar comparisons were performed
Table 2: Panel of antibodies.
Antigen/antibody Dilution Source
CD4 1 : 25 Dako
CD8 1 : 25 Dako
CD34 1 : 50 Becton Dickinson
CD44 variant 3 1 : 10 Menarini
CD45RO 1 : 100 Dako
CD68 1 : 200 Dako
Cytokeratin 15 1 : 1 Neomarkers
Factor XIIIa 1 : 100 Neomarkers
Glutathione S transferase 𝜋 1 : 100 Castra Lab.
Ki-67 1 : 100 Dako
Lysozyme 1 : 300 Dako
Mac 387 1 : 400 Dako
Myeloperoxidase 1 : 1000 Dako
Ulex europaeus agglutinin-1 1 : 2000 Sigma
Versican 1 : 500 Seikagaku Corp.
in each condition to assess the relative densities of lym-
phocytes and macrophages. A 𝑃 value lower than 0.05 was
considered statistically significant.
3. Results
3.1. Lymphocytes. T lymphocytes were scanty in the three
conditions. Skin-infiltrating lymphocytes in GVHR were
memory CD45RO+ T lymphocytes, as well as cells of the
CD4+ and CD8+ lineages. T lymphocytes grossly exhibited
similar patterns of distribution in TEN and GVHR. Amajor-
ity of them were present along the dermoepidermal junction,
and few of them were present inside the epidermis.These lat-
ter cells were predominantly CD8+ lymphocytes, whereas the
dermal inflammatory infiltrate was predominantly composed
ofCD4+ cells. By contrast, rare T lymphocyteswere identified
in recent PTTB. They were predominantly clustered in a
perivascular distribution.
The lymphocyte density showed large interindividual
differences in the three conditions (Table 3). No significant
difference was yielded between TEN and GVHR.
3.2. Macrophages. Mac 387+, CD68+, myeloperoxidase+,
and lysozyme+ macrophages were present in both TEN
and GVHR lesions (Table 3). They were located along the
dermoepidermal junction and haphazardly dispersed in both
the dermis and epidermis. By contrast, these cells were rare
in PTTB.
In each condition, the Mac 387+ macrophage density
was significantly (𝑃 < 0.01) superior to the CD45RO+
lymphocytes.
3.3. Dermal Resident Cells. Factor XIIIa+ DD appeared
numerous and plump in the superficial dermis of most TEN
and GVHR (Table 3). By contrast, PTTB did not apparently
alter the Factor XIIIa+ DD population. Of note, the CD34+
DD remained tiny and rare in the three conditions.
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Table 3: Medians (ranges) of cell densities/mm2 in the epidermis
and superficial dermis of TEN, acute GVHR, and PTTB.
Cells/marker TEN GVHR PTTB
Dermal T lymphocytes
CD45RO 8 (2–19) 13 (9–29) 5 (1–9)
CD4 4 (0–10) 9 (5–16) 2 (0–6)
CD8 2 (0–5) 3 (0–6) 1 (0–3)
Dermal macrophages
Mac 387 17 (9–31) 19 (13–38) 6 (1–8)
CD68 6 (3–10) 9 (5–17) 1 (0–4)
Myeloperoxidase 4 (3–9) 3 (2–8) 0 (0–3)
Lysozyme 5 (3–8) 10 (3–16) 1 (0–5)
Dermal dendrocytes
Factor XIIIa 48 (24–65) 61 (45–83) 52 (33–68)
CD34 9 (6–15) 12 (8–17) 12 (5–16)
Versican 15 (7–32) 19 (14–42) 8 (3–17)
Keratinocytes
Mac 387 389 (206–551) 296 (157–319) 29 (20–39)
UEA-1 97 (33–197) 78 (12–94) 33 (6–81)
CD44 var 3 408 (396–569) 333 (315–378) 15 (12–218)
GST𝜋 32 (0–95) 15 (3–61) 0 (0–4)
Ki67 6 (0–19) 9 (7–42) 15 (0–63)
CK15 3 (0–8) 1 (0–4) 4 (0–7)
Versican filled up most dermal cells in TEN and GVHR.
They appeared plump compared to those in PTTB. In each
condition, they were evenly distributed in the superficial
dermis.
3.4. Keratinocytes. L1-protein+ (Mac 387+) keratinocytes
were present in all cases of TEN, GVHR, and PTTB
irrespective of the histopathologic grades. The cytoplasmic
staining was focal or diffuse throughout the epidermis layers,
even when the dermal inflammatory infiltrate was scant.
Similarly, an uneven to strong Mac 387+ immunolabeling of
keratinocytes was present in all biopsies of TEN-altered skin.
The L1-antigen was, however, expressed mainly in suprabasal
layers of TEN epidermis, with more discrete involvement of
basal keratinocytes. The majority of samples from apparently
uninvolved skin in TEN patients expressed the L1-antigen
in a patchy pattern inside the epidermis, at sites where
inflammatory cells were scanty or absent. In PTTB, all
keratinocytes showed an intense L1-antigen labeling.
Ulex europaeus agglutinin UEA type I labeled the upper
portion or the whole epidermis in the three conditions.
The CD44 var 3 immunoreactivity surrounded each
keratinocyte and was not altered by any of the assessed skin
conditions.
Glutathione S transferase (GST) 𝜋 was disclosed in small
clusters of superficial keratinocytes in TEN.
The Ki-67 labeling was absent or very low (<2% basal
cells) in the three conditions exhibiting large areas of ker-
atinocyte necrosis.
The cytokeratin (CK) 15 was disclosed in rare (<1%) basal
cells.
4. Discussion
TEN is one of the most dramatic drug-induced SCAR [1].
This life-threatening disease is characterized by the extensive
destruction of the epidermis and epithelial mucosae. Some
clues suggest that TEN results from a specific alteration of
drug metabolism in keratinocytes [11, 15, 47]. More than
100 different drugs are currently involved in TEN, but only
a minority of them accounts for the vast majority of cases
[8]. Molecular and morphologic features of apoptosis were
demonstrated in TEN-involved keratinocytes during the
initial stage of the disease [13–15].The following phase of TEN
is characterized by full-thickness epidermal necrosis. Hence,
it is assumed that the TEN pathomechanism likely combines
early apoptosis and late necrosis [13, 14].
GVHR is recognized by clinicopathological alterations
in recipients of HCT or bone marrow transplantation [21,
22]. Both immunological and nonspecific phenomena con-
tribute to the clinical aspects. GVHR is one of the major
complications of HCT and is responsible for postthera-
peutic morbidity, decreased quality of life, and mortality
[21, 22]. GVHR is critically induced and maintained by
donor immunocompetent cells that are particularly directed
against epithelia showing fast renewal including the liver,
gastrointestinal tract, and epidermis.
In some instances, a clinicopathological overlap exists
between aspects of GVHR and TEN. This mixed con-
dition typically represents a puzzling diagnostic dilemma
[27, 44, 46]. Histopathology of both conditions shows a
sparse inflammatory cell infiltrate with keratinocyte apop-
tosis. Satellite cell necrosis has been thought to be a typical
feature ofGVHR, although the same aspect has similarly been
recorded in some TEN cases.
Until recently, macrophages were unfrequently reported
in TEN and GVHR, and they were not considered to play a
pivotal role in the disease. However, biopsies from the liver,
gut, and skin of patients with lethal GVHR showed a striking
preponderance of CD68+ macrophages in the inflammatory
infiltrate. They were variably reported to be more or less
numerous than T lymphocytes. The macrophage prepon-
derance was especially found in the most severely damaged
skin areas [27]. Indeed, themonocyte/macrophage L1-protein
(Mac 387) expression was reported in over 80% of GVHR,
but their possible primary or secondary involvement still
remains debated. The preponderant macrophage infiltrate
occasionally observed might result from the antilymphocyte
effect achieved by preventive immunosuppressive treatments
that generally do not target macrophages. However, this
possibility does not rule out that primary macrophage-
mediated GVHR exists. In such instance, GVHR resembles
the inflammatory reaction to imiquimod application of the
skin [48].
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Macrophages could tentatively serve as a clue distinguish-
ing TEN andGVHR.When the immunosuppressive regimen
to HSCT fails to perform adequately, cutaneous GVHR
shows a predominance of T lymphocytes over macrophages.
Nowadays, the histopathological presentation of GVHR has
changed, with refinements in the biologic and pharmacologic
prevention of HSCT adverse effects. As immunosuppressive
regimen preferentially targets T lymphocytes, the inflamma-
tory reaction becomes restricted to Mac 387+ macrophages.
The latter cells always outnumber the CD68+, myeloper-
oxidase+, and lysozyme+ macrophages. They are at least
as numerous as the combination of CD45RO+, CD4+, and
CD8+ T lymphocytes in TEN and even more abundant
in recent cases. Even when macrophages outnumber T
lymphocytes in TEN, a pure macrophage infiltrate is never
seen. Hence, an inflammatory infiltrate composed almost
exclusively of Mac 387+ macrophages could be a clue for a
lymphocyte-abated GVHR.
FactorXIIIa+DDencompass distinct functional subtypes
[49]. Their numbers in the superficial dermis are variable
and appear increased in the vast majority of TEN cases [18].
The large number of Factor XIIIa+ DD and their plump
appearance in the perilesional and lesional TEN skin suggest
their activation during the initial steps of the disease. The
CD34+ DD do not show similar stimulation signs. The
Factor XIIIa+ DD ultrastructural aspects are similar in TEN
and GVHR, showing enlarged endoplasmic reticulum, and
phagocytosis of collagen fibres and mast cell granules [39]. It
is inferred that both the number and aspect of DDdo not help
discriminating the two diseases. They provide an additional
link between them. Similarly, the versican+ dendritic cells
appear stimulated in TEN and GVHR.
Keratinocytes are clearly the main target cells in both
TEN and GVHR. Several immunohistochemical markers
identifying keratinocytes and their adhesion molecules have
been proposed to reveal changes in the epidermis of these
two conditions [27]. The 365-kDa L1-protein exhibits some
antimicrobial properties. The name calprotectin was coined
for it. It is specifically identified using the Mac 387 mono-
clonal antibody during routine immunostaining. It consists
of three calcium noncovalently bound polypeptide chains. It
is expressed in neutrophils, monocytes, and some reactive
macrophages, as well as in mucosal epithelium and reactive
epidermis. Keratinocytes in the vicinity of inflammatory
cells or covering tumors frequently express the L1-protein, a
conditionwhich has been interpreted as a nonspecificmarker
of cellular stress. The L1-protein keratinocyte expression
during GVHR probably discloses sublethal cell injury. Such
a finding appears to be very sensitive, although it lacks
specificity. Hence, epidermal L1-protein expression is not
specific and cannot be used for distinguishing GVHR from
TEN.
In the present study, immunohistochemistry directed
to UEA-1, CD44 var 3, and CK15 did not reveal marked
differences between TEN and GVHR keratinocytes. The
number of Ki67+ keratinocytes engaged in cell proliferation
was similar in these two conditions. By contrast, it was largely
overexpressed in some PTTB cases engaged in a repair phase.
By contrast, the GST𝜋 immunolabeling was more frequently
overexpressed in TEN than in GVHR, and it was often absent
in PTTB.
5. Conclusion
TEN, GVHR, and PTTB share in common extensive necrosis
of the full-thickness epidermis. The induction mechanisms
are strikingly distinct, involving a drug cytotoxic reaction in
TEN, a lymphocyte-mediated destruction in GVHR, and a
physical threat in PTTB. The clinicopathological differential
diagnosis between TEN and acute GVHR is blurred by
overlaps in the skin conditions. This retrospective study
suggests that themacrophage/lymphocyte balance represents
a clue for distinguishing both conditions.
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